Latest Breaking News On - Johnson company - Page 16 : vimarsana.com

Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy

Media contact: Investor contact: .

United statesRegion flamandeEdmond chanJenni mildonCiltacabtagene autoleucelEuropean commission grants conditional approvalLegend biotech united states incJanssen biotech incDrug administrationAmerican society of clinical oncologyEuropean commissionJanssen cilag internationalChinese company legend biotech to develop investigationalAmerican cancer societyCommittee for orphan medicinal productsJanssen research development

European Commission Approves Cilta-Cel for Relapsed/Refractory Multiple Myeloma

Cilta-cel has received approval from the European Commission for multiple myeloma that is relapsed or refractory to at least 1 prior line of therapy.

Edmond chanJohnson companyEuropean commissionTherapeutic area lead for haematology at janssen cilagSan miguelTranslational medicineUniversidad de navarraArea leadJanssen cilag limitedMultiple myelomaJohnson innovative medicineCilta celJesús san miguelMultiple myeloma that is relapsed or refractory

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesNew havenAlloimmune thrombocytopeniaRallybio corporation nasdaqMomenta pharmaceuticals incJohnson companyJjdc incExchange commissionAnnounces collaborationAdvance therapeutic solutionsPregnant individualsNeonatal alloimmune thrombocytopeniaJohnson innovationStephen udenChief executive officerAnnual report

Global Orthopedic Trauma Devices Industry is expected to grow at a 6 4% CAGR to reach an astounding US$ 21 24 Billion by 2034 | FMI

Global Orthopedic Trauma Devices Industry is expected to grow at a 6 4% CAGR to reach an astounding US$ 21 24 Billion by 2034 | FMI
fmiblog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fmiblog.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkB braun melsungenAsia pacificStryker corporationSmith nephew plcSh pitkar orthotools pvt ltdGreater new york chamberDepuy synthes incZimmer holding incWeigao group co ltdJohnson services incArthrex incInvibio ltdWright medical groupOlympus corporation

Juvisé Pharmaceuticals Acquires Multiple Sclerosis Drug PONVORY® (ex-US/Canada) and Opens Its Capital to Bpifrance and Pemberton

Juvisé Pharmaceuticals Acquires Multiple Sclerosis Drug PONVORY® (ex-US/Canada) and Opens Its Capital to Bpifrance and Pemberton
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesBredin pratSprengert ponesimodLatham watkinsActelion pharmaceuticals ltdPharmaceuticals acquires multiple sclerosis drugJohnson companyOpens its capitalPemberton asset managementDisease modifying treatmentAnnualized relapse rateCompared with teriflunomidePatients with relapsing multiple sclerosisActive comparator phaseRandomized clinical